ResMed's Management Hosts Deutsche Bank AG Health Care Conference Call (Transcript)

ResMed Inc. (RMD)

Deutsche Bank AG Health Care Conference Call

May 8, 2012 10:00 am EDT

Executives

David Pendarvis – Chief Administrative Officer and Global General Counsel

Analysts

David Low – Deutsche Bank

Presentation

David Low – Deutsche Bank

Good morning, everyone. My name is David Low. I cover Healthcare stocks out of Australia, including ResMed, which has obviously got dual listing. Today, we've got David Pendarvis, who is the Chief Administrative Officer at ResMed. David's got ten years' experience at ResMed. And he's going to give us a presentation and then take a few questions. Thanks very much, David.

David Pendarvis

Fantastic. Thank you, David, and thanks to Deutsche Bank for having us, and for covering the ResMed both here, obviously, and down on the Australian Stock Exchange, where we are dual listed. So, the forward-looking statements, obviously, hold on to your seat belts when we predict things, we can at sometimes be wrong. And I want to really focus on sort of three main points here.

If you take nothing else away from this presentation, it's that ResMed really is sort of the Holy Grail of healthcare, in the sense that we do three things, we prevent disease, in particular the disease of sleep apnea and we improve the quality of life.

But, we also reduced the cost of health care. So, as systems around the world are trying to struggle with delivering higher quality for less cost. We do that and we do that in this space. So, those are really the three primary things that ResMed delivers here.

The company focuses on both developing to an extensive R&D program and a manufacturing with manufacturing plants, primarily based in Australia as well as in Singapore and Malaysia with some component factories in the U.S. We manufacture our own devices and then we distribute, primarily through wholesaling our products although we do have some direct-to-patient sales throughout the world of medical devices and the bulk of our sales are therapy devices that are meant to treat sleep-disorder breathing. But, we also have ventilatory assistance for other respiratory conditions.

So, primarily and what a lot of the focus of the presentation in business really is about is about sleep-disordered breathing, but we do have another significant business in the sense of dealing with our ventilation sales.

So, we have several things that we do to in order to achieve the Holy Grail. First of all, we focus on innovation. We've got innovative products and technology We are consistently raising the bar to try to make sure that there is effective diagnosis, that therapeutic options that are available to patients are effective and they're going to treat the scourge of sleep disorder breathing, but also the patients are comfortable and they are able to actually want to use their devices so that they get the benefits from them.

And we are consistently doing that and we have done that for the 20 years of the company's existence. We’re also continuing to promote education and awareness. Because we don't want to simply react to the market, we want to help drive the market and as a market leader, we want to consistently make sure that folks are aware of both in the patient community and in the physician community about the issues involved in sleep disorder breathing and the opportunities that there are to have this condition treated and the impact that it can have, not only on the quality of life for someone who is suffering from sleep disorder breathing, but also in other aspects of their life and other aspects of their health.

As I mentioned before we have ventilation, we also recently came out with a significant launch of a monitoring system that basically a patient management system called EasyCare online and I will get to that in a moment. The market opportunity continues to be enormous here 20% of the adult population has sleep apnea and 7% about a third of that if you will is a moderate to severe case meaning you start breathing 15 or more times an hour and mild cases represent about 13% of the adult population.

As ongoing obesity, which I’ll get to in a little bit, but it is topical because if those of you who are fans of the USA today arrived outside your hotel room today, you would have seen the CDC that U.S. centers for disease control issued a report yesterday predicting that the obesity rates in the United States are going to get to 42% of adults by 2030.

So they are at about 36% now that 6% increase by 2030 of the CDC’s predictions prove to be correct we are going to cause enormous healthcare cost to the entire U.S. healthcare system. A lot of those costs are driven and on the other hand can be ameliorated by effective treating for sleep apnea because obviously patients who are significantly obese have significant high rates of sleep apnea.

The sleep disorder breathing is, as many of you are familiar here the guy on the left is healthy, he is breathing clearly while he sleeps, the middle guy here has got a (Inaudible) up where you can see this tongue, muscle of the tongue is rolling back, upper airway is starting to close and then you have fully obstructed air way with whereas the guy on the far left is getting the blue representing the air getting down into the lungs. The

Read the rest of this transcript for free on seekingalpha.com

More from Stocks

A Hungry Grizzly Bear Is Stalking the Stock Market

A Hungry Grizzly Bear Is Stalking the Stock Market

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Why Most Americans Like a Volatile Stock Market: Study

Why Most Americans Like a Volatile Stock Market: Study

Should Retirees Invest in the Tech Sector?

Should Retirees Invest in the Tech Sector?

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings